Hypertrophic pachymeningitis in rheumatoid arthritis after adalimumab administration

Journal of Rheumatology

Volumn 33, Issue 11, 2006, Pages 2344-2346

  Ahmed, Mansoor ^a   Luggen, Michael ^a   Herman, Jerome H ^b   Weiss, Kenneth L ^c   Decourten Myers, Gabrielle ^c   Quinlan, John G ^c   Khanna, Dinesh ^a,b  

^a Division of Immunology   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Department of Radiology ^*

Author keywords

Adalimumab; Pachymeningitis; Rheumatoid arthritis; Tumor necrosis factor alpha

Indexed keywords

ACICLOVIR; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AGED; ARTICLE; BRAIN BIOPSY; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CONFUSION; DEMYELINATING DISEASE; DISEASE EXACERBATION; DRUG WITHDRAWAL; DYSPHASIA; HEADACHE; HUMAN; HUMAN TISSUE; HYPERTROPHIC PACHYMENINGITIS; INVOLUNTARY MOVEMENT; MALE; MENINGITIS; MENINGOENCEPHALITIS; PRIORITY JOURNAL; RARE DISEASE; RECURRENCE RISK; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYMPTOMATOLOGY;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HISTOCYTOCHEMISTRY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MENINGITIS; PREDNISONE;

EID: 33750967645     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Kupersmith MJ, Martin V, Heller G, Shah A, Mitnick HJ. Idiopathic hypertrophic pachymeningitis. Neurology 2004;62:686-94.
2. Prabhakar S, Bhatia R, Lal V, Singh P. Hypertrophic pachymeningitis: varied manifestations of a single disease entity. Neurol India 2002;50:45-52.
3. Riku S, Kato S. Idiopathic hypertrophic pachymeningitis. Neuropathology 2003;23:335-44.
4. Tan HJ, Raymond AA, Phadke PP, Rozman Z. Rheumatoid pachymeningitis. Singapore Med J 2004;45:337-9.
5. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004;27:307-24.
6. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001;44:1977-83.
7. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999;53:457-65.
8. Miller FW, Hess EV, Clauw DJ, et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 2000;43:243-9.
9. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
10. Rosenbaum R, Campbell S, Rosenbaum J. Clinical neurology of rheumatic diseases. Boston: Butterworth-Heinemann; 1996.